COMMUNIQUÉS West-GlobeNewswire

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
21/08/2025
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease [...]
Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th
21/08/2025
WESTBROOK, Maine, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is confirmed to present at the 2025 Annual Gateway [...]
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
21/08/2025
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a [...]
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
21/08/2025
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Pyxis Oncology to Participate in September Investor and Industry Conferences
21/08/2025
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. [...]
InflaRx Announces Participation in September Investor Conferences
21/08/2025
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
21/08/2025
This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv ™ Rx device is pending Premarket [...]
Kraig Biocraft Laboratories Announces Commencement of Full Operations at Second Production Rearing Center in Southeast Asia
21/08/2025
Parallel facilities strengthen continuous production and accelerate spider silk advancements ANN ARBOR, Mich., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs [...]
BioCryst to Present at Upcoming Investor Conference
21/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on [...]
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
21/08/2025
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI [...]
Unleashing the Spirit of Adventure: Breckenridge Distillery Launches Mountain Shot, a Bold New Mushroom-Infused Elixir
21/08/2025
Mountain Shot Delivers an Elevated Whiskey Experience, Blending Smooth Chocolate Notes with a Refreshing Hint of Mint BRECKENRIDGE, Colo., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery , an award-winning [...]
I-Mab to Participate in September Investor Conferences
21/08/2025
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, [...]
BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
21/08/2025
POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for [...]
Castle Biosciences to Participate in Upcoming Investor Conferences
21/08/2025
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management [...]
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
21/08/2025
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield
21/08/2025
Expanded credit facility to fund initial post-harvest buildout at Valleyfield, supporting the Company’s long-term goal of reaching 100,000 kg annual capacity MONTREAL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech [...]
Cannara annonce la modification et l’augmentation de la facilité de crédit accordée par BMO afin de soutenir l’expansion de ses installations à Valleyfield
21/08/2025
La facilité de crédit élargie servira à financer la construction initiale post-récolte à Valleyfield, soutenant ainsi l’objectif à long terme de la Société d’atteindre une capacité annuelle de 100 000 kg MONTRÉAL, 21 [...]
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
21/08/2025
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on [...]
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
21/08/2025
Mynzepli ® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on [...]

Pages